Search
Spero Therapeutics Inc
SPROAdd to Watchlist
2.200USD
-0.020-0.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
127.38MMarket Cap
7.92P/E TTM
More Details of Spero Therapeutics Inc Company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc Info
Ticker SymbolSPRO
Company nameSpero Therapeutics Inc
IPO dateNov 02, 2017
CEORajavelu (Esther)
Number of employees32
Security typeOrdinary Share
Fiscal year-endNov 02
Address675 Massachusetts Ave Ste 14
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139-3309
Phone18572421600
Websitehttps://sperotherapeutics.com/
Ticker SymbolSPRO
IPO dateNov 02, 2017
CEORajavelu (Esther)
Company Executives of Spero Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
-36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
FAQs
Who are the top five shareholders of Spero Therapeutics Inc?
The top five shareholders of Spero Therapeutics Inc are: Dr. Ankit Mahadevia, M.D.
How many institutions hold shares of Spero Therapeutics Inc (SPRO)?
As of 2026Q1, 117 institutions hold shares of Spero Therapeutics Inc, with a combined market value of approximately 11.81M, accounting for 20.40% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1291189.00.
What is the biggest source of revenue for Spero Therapeutics Inc?
In 2026Q1, the Collaboration Revenue Related Party business generated the highest revenue for Spero Therapeutics Inc, amounting to 47.03M and accounting for 70.41% of total revenue.